NCT07022002 - SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors | Biotech Hunter

Enrollment

340

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 12, 2027

Conditions

Locally Advanced, Recurrent or Metastatic Malignancies

Interventions

DRUG

SSGJ-705

anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody

DRUG

PD-1/L1 inhibitor combined with chemotherapy

Immune checkpoint inhibitors

DRUG

SSGJ-705 combined with chemotherapy

anti-PD-1 and anti-HER2 bispecifc antibody

Trial Locations (1)

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY